
Chinese General Practice ›› 2025, Vol. 28 ›› Issue (26): 3229-3239.DOI: 10.12114/j.issn.1007-9572.2024.0652
Special Issue: 心血管最新文章合辑; 肥胖/减重最新文章合辑
• Original Research • Previous Articles Next Articles
Received:2024-09-10
Revised:2025-02-20
Published:2025-09-15
Online:2025-07-22
Contact:
FENG Wenhuan
通讯作者:
冯文焕
作者简介:作者贡献:
向心月负责临床数据收集、整理、分析,并撰写论文初稿;张冰青负责绘制图表并协助统计分析;欧阳煜钦负责临床资料质量把控,协助初稿撰写;汤文娟完善论文的审校;冯文焕提出研究思路,设计研究方案,完善论文最终内容及审校,并对论文负责。
基金资助:CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2024.0652
| 临床指标 | 治疗前 | 治疗3个月 | 检验统计量值 | P值 |
|---|---|---|---|---|
| ASCVD风险[例(%)] | 21.109a | <0.001 | ||
| 低危 | 114(66.3) | 150(87.2) | ||
| 中高危 | 58(33.7) | 22(12.8) | ||
| 体质量[M(P25,P75),kg] | 89.8(82.0,101.2) | 82.5(72.9,91.9) | -9.254 | <0.001 |
| BMI[M(P25,P75),kg/m2] | 31.6(30.0,33.9) | 28.8(27.0,30.7) | -10.238 | <0.001 |
| 腰围[M(P25,P75),cm] | 101.3(95.0,109.8) | 94(88.1,101.0) | -8.950 | <0.001 |
| 腰高比[M(P25,P75)] | 0.6(0.5,0.6) | 0.5(0.5,0.6) | -8.958 | <0.001 |
| 体脂肪[M(P25,P75),kg] | 34.3(29.9,39.5) | 28(22.8,32.7) | -9.565 | <0.001 |
| 体脂百分比[M(P25,P75),%] | 39.2(34.4,43.0) | 34.2(28.4,39.7) | -8.849 | <0.001 |
| FMI[M(P25,P75),kg/m2] | 12.2(10.5,13.8) | 10.0(7.9,11.4) | -8.923 | <0.001 |
| VFA[M(P25,P75),cm2] | 166.5(141.5,186.8) | 131.5(96.7,157.8) | -5.361 | <0.001 |
| ASMI[M(P25,P75),kg/m2] | 8.1(7.5,8.9) | 7.9(7.2,8.7) | -4.981 | <0.001 |
| 总肌肉量[M(P25,P75),kg] | 51.9(45.8,60.0) | 50.6(43.7,59.0) | -9.586 | <0.001 |
| 心率( | 89.5±12.4 | 88.9±12.5 | 0.487b | 0.627 |
| SBP( | 129±12 | 121±11 | 7.633b | <0.001 |
| DBP( | 83±10 | 78±9 | 5.093b | <0.001 |
| FBG [M(P25,P75),mmol/L] | 5.4(4.9,5.8) | 4.9(4.6,5.2) | -7.070 | <0.001 |
| 2 hFBG[M(P25,P75),mmol/L] | 7.9(6.6,9.8) | 6.4(5.4,7.1) | -7.157 | <0.001 |
| FINS[M(P25,P75),mU/L] | 17.5(13.3,26.9) | 13.3(8.8,17.1) | -7.075 | <0.001 |
| 2 hFINS[M(P25,P75),mU/L] | 126.8(88.5,202.7) | 87.7(56.3,118.7) | -5.556 | <0.001 |
| HOMA-IR [M(P25,P75)] | 4.1(3.1,6.4) | 2.4(1.0,3.5) | -8.600 | <0.001 |
| TG[M(P25,P75),mmol/L] | 1.8(1.3,2.3) | 1.3(0.9,1.7) | -6.489 | <0.001 |
| TC[M(P25,P75),mmol/L] | 4.8(4.4,5.5) | 4.5(3.9,4.9) | -4.716 | <0.001 |
| HDL-C[M(P25,P75),mmol/L] | 1.1(0.9,1.3) | 1.1(1.0,1.2) | -0.783 | 0.434 |
| LDL-C[M(P25,P75),mmol/L] | 3.1(2.6,3.5) | 2.6(2.2,3.0) | -6.787 | <0.001 |
| UA( | 428.4±122.9 | 383.3±95.0 | 3.497b | <0.001 |
| ALT[M(P25,P75),U/L] | 42.2(22.4,69.5) | 25.6(16.6,38.3) | -7.220 | <0.001 |
| AST[M(P25,P75),U/L] | 25.6(19.5,38.5) | 21.0(16.8,26.5) | -5.569 | <0.001 |
Table 1 Changes in various clinical indicators before treatment and after 3 months of treatment in the study subjects
| 临床指标 | 治疗前 | 治疗3个月 | 检验统计量值 | P值 |
|---|---|---|---|---|
| ASCVD风险[例(%)] | 21.109a | <0.001 | ||
| 低危 | 114(66.3) | 150(87.2) | ||
| 中高危 | 58(33.7) | 22(12.8) | ||
| 体质量[M(P25,P75),kg] | 89.8(82.0,101.2) | 82.5(72.9,91.9) | -9.254 | <0.001 |
| BMI[M(P25,P75),kg/m2] | 31.6(30.0,33.9) | 28.8(27.0,30.7) | -10.238 | <0.001 |
| 腰围[M(P25,P75),cm] | 101.3(95.0,109.8) | 94(88.1,101.0) | -8.950 | <0.001 |
| 腰高比[M(P25,P75)] | 0.6(0.5,0.6) | 0.5(0.5,0.6) | -8.958 | <0.001 |
| 体脂肪[M(P25,P75),kg] | 34.3(29.9,39.5) | 28(22.8,32.7) | -9.565 | <0.001 |
| 体脂百分比[M(P25,P75),%] | 39.2(34.4,43.0) | 34.2(28.4,39.7) | -8.849 | <0.001 |
| FMI[M(P25,P75),kg/m2] | 12.2(10.5,13.8) | 10.0(7.9,11.4) | -8.923 | <0.001 |
| VFA[M(P25,P75),cm2] | 166.5(141.5,186.8) | 131.5(96.7,157.8) | -5.361 | <0.001 |
| ASMI[M(P25,P75),kg/m2] | 8.1(7.5,8.9) | 7.9(7.2,8.7) | -4.981 | <0.001 |
| 总肌肉量[M(P25,P75),kg] | 51.9(45.8,60.0) | 50.6(43.7,59.0) | -9.586 | <0.001 |
| 心率( | 89.5±12.4 | 88.9±12.5 | 0.487b | 0.627 |
| SBP( | 129±12 | 121±11 | 7.633b | <0.001 |
| DBP( | 83±10 | 78±9 | 5.093b | <0.001 |
| FBG [M(P25,P75),mmol/L] | 5.4(4.9,5.8) | 4.9(4.6,5.2) | -7.070 | <0.001 |
| 2 hFBG[M(P25,P75),mmol/L] | 7.9(6.6,9.8) | 6.4(5.4,7.1) | -7.157 | <0.001 |
| FINS[M(P25,P75),mU/L] | 17.5(13.3,26.9) | 13.3(8.8,17.1) | -7.075 | <0.001 |
| 2 hFINS[M(P25,P75),mU/L] | 126.8(88.5,202.7) | 87.7(56.3,118.7) | -5.556 | <0.001 |
| HOMA-IR [M(P25,P75)] | 4.1(3.1,6.4) | 2.4(1.0,3.5) | -8.600 | <0.001 |
| TG[M(P25,P75),mmol/L] | 1.8(1.3,2.3) | 1.3(0.9,1.7) | -6.489 | <0.001 |
| TC[M(P25,P75),mmol/L] | 4.8(4.4,5.5) | 4.5(3.9,4.9) | -4.716 | <0.001 |
| HDL-C[M(P25,P75),mmol/L] | 1.1(0.9,1.3) | 1.1(1.0,1.2) | -0.783 | 0.434 |
| LDL-C[M(P25,P75),mmol/L] | 3.1(2.6,3.5) | 2.6(2.2,3.0) | -6.787 | <0.001 |
| UA( | 428.4±122.9 | 383.3±95.0 | 3.497b | <0.001 |
| ALT[M(P25,P75),U/L] | 42.2(22.4,69.5) | 25.6(16.6,38.3) | -7.220 | <0.001 |
| AST[M(P25,P75),U/L] | 25.6(19.5,38.5) | 21.0(16.8,26.5) | -5.569 | <0.001 |
| 指标 | 低危组(n=114) | 中高危组(n=58) | 检验统计量值 | P值 |
|---|---|---|---|---|
| 性别[例(%)] | 0.726a | 0.079 | ||
| 男 | 43(37.7) | 30(51.7) | ||
| 女 | 71(62.3) | 28(48.3) | ||
| 年龄[M(P25,P75),岁] | 31.0(27.0,37.3) | 34.0(28.0,39.3) | -1.261 | 0.207 |
| 身高[M(P25,P75),cm] | 166.0(162.0,174.3) | 170.0(164.5,178.0) | -1.912 | 0.056 |
| 体质量[M(P25,P75),kg] | 89.6(80.0,99.1) | 91.4(83.7,105.2) | -1.817 | 0.069 |
| BMI[M(P25,P75),kg/m2] | 31.5(29.9,33.5) | 31.85(29.9,34.3) | -1.119 | 0.263 |
| 腰围[M(P25,P75),cm] | 100(94,109) | 102(96,110) | -1.152 | 0.249 |
| 腰高比[M(P25,P75)] | 0.6(0.6,0.6) | 0.6(0.6,0.7) | -0.321 | 0.748 |
| 体脂肪[M(P25,P75),kg] | 34.1(28.7,38.7) | 34.6(31.2,40.5) | -1.485 | 0.266 |
| 体脂百分比[M(P25,P75),%] | 39.7(33.7,43.0) | 37.8(34.8,43.0) | -0.117 | 0.952 |
| FMI[M(P25,P75),kg/m2] | 12.2(10.4,13.7) | 12.2(10.6,14.0) | -0.536 | 0.642 |
| VFA[M(P25,P75),cm2] | 165.5(133.3,186.0) | 168.9(147.0,190.9) | -0.943 | 0.485 |
| ASMI[M(P25,P75),kg/m2] | 8.1(7.5,8.9) | 8.3(7.7,9.2) | -0.913 | 0.361 |
| 总肌肉量[M(P25,P75),kg] | 50.1(45.1,59.2) | 54.5(46.5,62.8) | -1.527 | 0.144 |
| 心率( | 89.6±13.4 | 89.5±10.4 | 0.055b | 0.959 |
| SBP( | 129±12 | 129±12 | -0.233b | 0.816 |
| DBP( | 82±11 | 84±9 | -0.752b | 0.453 |
| FBG [M(P25,P75),mmol/L] | 5.2(4.9,5.6) | 5.5(4.9,6.2) | -2.034 | 0.019 |
| 2 hFBG[M(P25,P75),mmol/L] | 7.4(6.5,8.7) | 8.4(6.9,11.4) | -2.541 | 0.011 |
| FINS[M(P25,P75),mU/L] | 16.8(13.2,26.8) | 21.7(13.2,33.2) | -1.769 | 0.242 |
| 2 hFINS[M(P25,P75),mU/L] | 115.5(84.7,208.3) | 156.1(109.0,237.5) | -2.476 | 0.041 |
| HOMA-IR [M(P25,P75)] | 4.1(3.1,6.2) | 5.3(3.2,8.6) | -2.471 | 0.004 |
| TG[M(P25,P75),mmol/L] | 1.6(1.3,2.2) | 2.1(1.5,3.4) | -3.276 | 0.001 |
| TC[M(P25,P75),mmol/L] | 4.8(4.2,5.2) | 5.2(4.6,5.9) | -3.252 | 0.001 |
| HDL-C[M(P25,P75),mmol/L] | 1.1(1.1,1.3) | 1.0(0.8,1.2) | -3.524 | <0.001 |
| LDL-C[M(P25,P75),mmol/L] | 3.1(2.5,3.4) | 3.4(2.9,3.7) | -2.946 | 0.003 |
| UA[M(P25,P75),mU/L] | 425.0(342.5,465.5) | 430.9(334.5,511.5) | -0.763 | 0.359 |
| ALT[M(P25,P75),U/L] | 38.4(21.0,62.6) | 50.0(28.0,89.7) | -2.350 | 0.022 |
| AST[M(P25,P75),U/L] | 24.6(18.4,36.8) | 29.3(20.3,54.5) | -2.411 | 0.022 |
Table 2 Comparison of clinical indicators before treatment between low-risk group and moderate-high risk group ASCVD patients
| 指标 | 低危组(n=114) | 中高危组(n=58) | 检验统计量值 | P值 |
|---|---|---|---|---|
| 性别[例(%)] | 0.726a | 0.079 | ||
| 男 | 43(37.7) | 30(51.7) | ||
| 女 | 71(62.3) | 28(48.3) | ||
| 年龄[M(P25,P75),岁] | 31.0(27.0,37.3) | 34.0(28.0,39.3) | -1.261 | 0.207 |
| 身高[M(P25,P75),cm] | 166.0(162.0,174.3) | 170.0(164.5,178.0) | -1.912 | 0.056 |
| 体质量[M(P25,P75),kg] | 89.6(80.0,99.1) | 91.4(83.7,105.2) | -1.817 | 0.069 |
| BMI[M(P25,P75),kg/m2] | 31.5(29.9,33.5) | 31.85(29.9,34.3) | -1.119 | 0.263 |
| 腰围[M(P25,P75),cm] | 100(94,109) | 102(96,110) | -1.152 | 0.249 |
| 腰高比[M(P25,P75)] | 0.6(0.6,0.6) | 0.6(0.6,0.7) | -0.321 | 0.748 |
| 体脂肪[M(P25,P75),kg] | 34.1(28.7,38.7) | 34.6(31.2,40.5) | -1.485 | 0.266 |
| 体脂百分比[M(P25,P75),%] | 39.7(33.7,43.0) | 37.8(34.8,43.0) | -0.117 | 0.952 |
| FMI[M(P25,P75),kg/m2] | 12.2(10.4,13.7) | 12.2(10.6,14.0) | -0.536 | 0.642 |
| VFA[M(P25,P75),cm2] | 165.5(133.3,186.0) | 168.9(147.0,190.9) | -0.943 | 0.485 |
| ASMI[M(P25,P75),kg/m2] | 8.1(7.5,8.9) | 8.3(7.7,9.2) | -0.913 | 0.361 |
| 总肌肉量[M(P25,P75),kg] | 50.1(45.1,59.2) | 54.5(46.5,62.8) | -1.527 | 0.144 |
| 心率( | 89.6±13.4 | 89.5±10.4 | 0.055b | 0.959 |
| SBP( | 129±12 | 129±12 | -0.233b | 0.816 |
| DBP( | 82±11 | 84±9 | -0.752b | 0.453 |
| FBG [M(P25,P75),mmol/L] | 5.2(4.9,5.6) | 5.5(4.9,6.2) | -2.034 | 0.019 |
| 2 hFBG[M(P25,P75),mmol/L] | 7.4(6.5,8.7) | 8.4(6.9,11.4) | -2.541 | 0.011 |
| FINS[M(P25,P75),mU/L] | 16.8(13.2,26.8) | 21.7(13.2,33.2) | -1.769 | 0.242 |
| 2 hFINS[M(P25,P75),mU/L] | 115.5(84.7,208.3) | 156.1(109.0,237.5) | -2.476 | 0.041 |
| HOMA-IR [M(P25,P75)] | 4.1(3.1,6.2) | 5.3(3.2,8.6) | -2.471 | 0.004 |
| TG[M(P25,P75),mmol/L] | 1.6(1.3,2.2) | 2.1(1.5,3.4) | -3.276 | 0.001 |
| TC[M(P25,P75),mmol/L] | 4.8(4.2,5.2) | 5.2(4.6,5.9) | -3.252 | 0.001 |
| HDL-C[M(P25,P75),mmol/L] | 1.1(1.1,1.3) | 1.0(0.8,1.2) | -3.524 | <0.001 |
| LDL-C[M(P25,P75),mmol/L] | 3.1(2.5,3.4) | 3.4(2.9,3.7) | -2.946 | 0.003 |
| UA[M(P25,P75),mU/L] | 425.0(342.5,465.5) | 430.9(334.5,511.5) | -0.763 | 0.359 |
| ALT[M(P25,P75),U/L] | 38.4(21.0,62.6) | 50.0(28.0,89.7) | -2.350 | 0.022 |
| AST[M(P25,P75),U/L] | 24.6(18.4,36.8) | 29.3(20.3,54.5) | -2.411 | 0.022 |
| 临床指标 | 治疗前 | 治疗3个月 | 组间评估平均差异(95%CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 中高危降低亚组(n=36) | 中高危不变亚组(n=22) | 检验统计量值 | P值 | 中高危降低亚组(n=36) | 中高危不变亚组(n=22) | 检验统计量值 | P值 | ||
| 体质量[M(P25,P75),kg] | 91.4(83.8,102.1) | 95.8(83.7,113.4) | -1.034b | 0.301 | 83.9(73.1,93.9)a | 84.6(76.8,102.7)a | -1.178b | 0.239 | 0.277(-9.573 ~10.127) |
| TWL( | 8.9±3.4 | 8.7±2.8 | 0.147 | 0.055 | |||||
| TWL≥5%[例(%)] | 22(61.1) | 12(54.5) | 0.243c | 0.622 | |||||
| TWL≥10%[例(%)] | 17(47.2) | 9(40.9) | 0.220c | 0.639 | |||||
| BMI( | 31.9±3.1 | 33.9±3.5 | -2.312 | 0.024 | 28.8±2.9a | 30.9±3.3a | -2.574 | 0.037 | 0.127(-2.114~2.367) |
| 腰围( | 102.6±9.9 | 105.9±12.3 | -1.134 | 0.262 | 96.7±10.1a | 98.4±12.3a | -0.575 | 0.568 | -1.630(-8.619~5.359) |
| 腰高比( | 0.6±0.1 | 0.6±0.1 | -1.125 | 0.186 | 0.6±0.1a | 0.6±0.1a | -0.621 | 0.389 | -0.009(-0.050~0.032) |
| 体脂肪( | 33.4±8.3 | 39.9±8.1 | -3.016 | 0.004 | 27.7±7.8a | 32.6±6.9a | -2.440 | 0.043 | -0.998(-6.461~4.464) |
| 体脂百分比( | 38.0±7.8 | 40.6±5.4 | -2.604 | 0.012 | 32.6±5.8a | 36.5±6.1* | -2.388 | 0.020 | 0.206(-4.218~4.629) |
| FMI( | 11.4±2.9 | 13.9±2.9 | -3.379 | 0.001 | 9.5±2.6a | 11.3±2.5a | -2.660 | 0.017 | -0.371(-2.299~1.557) |
| VFA( | 155.9±43.6 | 185.9±32.5 | -2.834 | 0.006 | 126.1±38.6a | 151.5±33.9a | -2.540 | 0.021 | -0.770(-28.099~26.558) |
| ASMI[M(P25,P75),kg/m2] | 8.2(7.3,9.0) | 8.5(7.7,9.5) | -1.194b | 0.233 | 8.1(7.4,8.8) | 8.1(7.4,9.2) | -0.288b | 0.868 | -0.497(-1.234~0.239) |
| 总肌肉量( | 54.7±10.4 | 55.3±10.8 | -0.118 | 0.906 | 54.2±10.1 | 53.9±11.7 | 0.064 | 0.949 | -0.516(-6.832~5.799) |
| 心率( | 88.7±10.0 | 90.7±11.0 | -0.711 | 0.480 | 87.3±13.0 | 89.7±12.0 | -0.725 | 0.471 | 0.391(-8.012~8.794) |
| SBP( | 128.9±12.8 | 128.8 ±9.6 | 0.041 | 0.968 | 119.1±12.1a | 124.9±10.3 | -1.889 | 0.064 | 5.976(-1.869~13.822) |
| DBP( | 84.2±9.0 | 82.5±9.6 | 0.682 | 0.498 | 78.0±10.7a | 79.8±9.2 | -0.655 | 0.515 | 3.504(-4.098~11.106) |
| FBG [M(P25,P75),mmol/L] | 5.5(5.0,6.7) | 5.5(4.7,6.5) | -0.687b | 0.575 | 5.0(4.7,5.4)a | 5.0(4.7,5.5) | -0.096b | 0.923 | 0.083(-1.412~1.577) |
| 2 hFBG[M(P25,P75),mmol/L] | 8.2(6.5,12.0) | 9.0(7.6,11.4) | -0.874b | 0.382 | 5.9(5.1,8.3) | 6.5(5.9,7.2)a | -0.849b | 0.396 | 0.186(-3.367~3.739) |
| FINS[M(P25,P75),mU/L] | 17.3(11.4,27.2) | 25.3(15.9,37.1) | -2.067b | 0.039 | 12.5(8.1,18.0)a | 15.9(11.2,22.3)a | -0.860b | 0.410 | -0.612(-13.812~12.588) |
| 2 hFINS( | 178.8±143.7 | 189.7±86.6 | -0.222 | 0.259 | 97.8±105.6a | 102.0±58.0a | -0.144 | 0.196 | 2.139(-85.107~89.384) |
| HOMA-IR [M(P25,P75)] | 4.8(3.2,7.5) | 6.2(3.4,10.9) | -0.902b | 0.178 | 2.9(1.6,4.0)a | 3.6(2.6,4.9)a | -0.578b | 0.088 | -0.207(-4.633~4.219) |
| TG[M(P25,P75),mmol/L] | 2.3(1.8,4.0) | 1.9(1.4,2.4) | -1.547b | 0.122 | 1.3(1.1,2.1)a | 1.5(1.0,1.9)a | -0.289b | 0.773 | 0.047(-1.257~1.351) |
| TC( | 5.2±1.7 | 5.1±0.8 | 0.066 | 0.466 | 4.5±1.0a | 4.9±0.6 | -1.591 | 0.074 | 0.408(-0.289~1.105) |
| HDL-C[M(P25,P75),mmol/L] | 1.1(0.8,1.4) | 0.9(0.8,1.1) | -2.052b | 0.040 | 1.1(0.9,1.2) | 1.0(0.9,1.1) | -1.515b | 0.990 | 0.278(0.010~0.545) |
| LDL-C( | 3.5±1.2 | 3.2±0.7 | 1.240 | 0.248 | 2.7±0.9a | 2.8±0.6 | -0.720 | 0.475 | 0.497(-0.109~1.105) |
| UA( | 444.5±115.5 | 443.2±159.1 | 0.072 | 0.973 | 404.2±124.0 | 392.4±101.6 | 0.387 | 0.974 | -16.362(-101.797~69.073) |
| ALT [M(P25,P75),U/L] | 48.5(23.5,118.1) | 48.5(32.2,88.8) | -0.706b | 0.841 | 26.0(17.6,40.8)a | 29.4(20.2,51.7)a | -0.215b | 0.654 | -3.427(-46.702~39.845) |
| AST[M(P25,P75),U/L] | 29.1(20.5,63.2) | 25.4(20.3,48.6) | -0.045b | 0.537 | 21.6(17.7,30.2)a | 21.9(17.8,31.8)a | -0.127b | 0.847 | 10.278(-24.631~45.189) |
Table 3 Comparison of indicators between the risk decreased group and the risk stable group after 3 months treatment in patients with moderate-high ASCVD risk
| 临床指标 | 治疗前 | 治疗3个月 | 组间评估平均差异(95%CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 中高危降低亚组(n=36) | 中高危不变亚组(n=22) | 检验统计量值 | P值 | 中高危降低亚组(n=36) | 中高危不变亚组(n=22) | 检验统计量值 | P值 | ||
| 体质量[M(P25,P75),kg] | 91.4(83.8,102.1) | 95.8(83.7,113.4) | -1.034b | 0.301 | 83.9(73.1,93.9)a | 84.6(76.8,102.7)a | -1.178b | 0.239 | 0.277(-9.573 ~10.127) |
| TWL( | 8.9±3.4 | 8.7±2.8 | 0.147 | 0.055 | |||||
| TWL≥5%[例(%)] | 22(61.1) | 12(54.5) | 0.243c | 0.622 | |||||
| TWL≥10%[例(%)] | 17(47.2) | 9(40.9) | 0.220c | 0.639 | |||||
| BMI( | 31.9±3.1 | 33.9±3.5 | -2.312 | 0.024 | 28.8±2.9a | 30.9±3.3a | -2.574 | 0.037 | 0.127(-2.114~2.367) |
| 腰围( | 102.6±9.9 | 105.9±12.3 | -1.134 | 0.262 | 96.7±10.1a | 98.4±12.3a | -0.575 | 0.568 | -1.630(-8.619~5.359) |
| 腰高比( | 0.6±0.1 | 0.6±0.1 | -1.125 | 0.186 | 0.6±0.1a | 0.6±0.1a | -0.621 | 0.389 | -0.009(-0.050~0.032) |
| 体脂肪( | 33.4±8.3 | 39.9±8.1 | -3.016 | 0.004 | 27.7±7.8a | 32.6±6.9a | -2.440 | 0.043 | -0.998(-6.461~4.464) |
| 体脂百分比( | 38.0±7.8 | 40.6±5.4 | -2.604 | 0.012 | 32.6±5.8a | 36.5±6.1* | -2.388 | 0.020 | 0.206(-4.218~4.629) |
| FMI( | 11.4±2.9 | 13.9±2.9 | -3.379 | 0.001 | 9.5±2.6a | 11.3±2.5a | -2.660 | 0.017 | -0.371(-2.299~1.557) |
| VFA( | 155.9±43.6 | 185.9±32.5 | -2.834 | 0.006 | 126.1±38.6a | 151.5±33.9a | -2.540 | 0.021 | -0.770(-28.099~26.558) |
| ASMI[M(P25,P75),kg/m2] | 8.2(7.3,9.0) | 8.5(7.7,9.5) | -1.194b | 0.233 | 8.1(7.4,8.8) | 8.1(7.4,9.2) | -0.288b | 0.868 | -0.497(-1.234~0.239) |
| 总肌肉量( | 54.7±10.4 | 55.3±10.8 | -0.118 | 0.906 | 54.2±10.1 | 53.9±11.7 | 0.064 | 0.949 | -0.516(-6.832~5.799) |
| 心率( | 88.7±10.0 | 90.7±11.0 | -0.711 | 0.480 | 87.3±13.0 | 89.7±12.0 | -0.725 | 0.471 | 0.391(-8.012~8.794) |
| SBP( | 128.9±12.8 | 128.8 ±9.6 | 0.041 | 0.968 | 119.1±12.1a | 124.9±10.3 | -1.889 | 0.064 | 5.976(-1.869~13.822) |
| DBP( | 84.2±9.0 | 82.5±9.6 | 0.682 | 0.498 | 78.0±10.7a | 79.8±9.2 | -0.655 | 0.515 | 3.504(-4.098~11.106) |
| FBG [M(P25,P75),mmol/L] | 5.5(5.0,6.7) | 5.5(4.7,6.5) | -0.687b | 0.575 | 5.0(4.7,5.4)a | 5.0(4.7,5.5) | -0.096b | 0.923 | 0.083(-1.412~1.577) |
| 2 hFBG[M(P25,P75),mmol/L] | 8.2(6.5,12.0) | 9.0(7.6,11.4) | -0.874b | 0.382 | 5.9(5.1,8.3) | 6.5(5.9,7.2)a | -0.849b | 0.396 | 0.186(-3.367~3.739) |
| FINS[M(P25,P75),mU/L] | 17.3(11.4,27.2) | 25.3(15.9,37.1) | -2.067b | 0.039 | 12.5(8.1,18.0)a | 15.9(11.2,22.3)a | -0.860b | 0.410 | -0.612(-13.812~12.588) |
| 2 hFINS( | 178.8±143.7 | 189.7±86.6 | -0.222 | 0.259 | 97.8±105.6a | 102.0±58.0a | -0.144 | 0.196 | 2.139(-85.107~89.384) |
| HOMA-IR [M(P25,P75)] | 4.8(3.2,7.5) | 6.2(3.4,10.9) | -0.902b | 0.178 | 2.9(1.6,4.0)a | 3.6(2.6,4.9)a | -0.578b | 0.088 | -0.207(-4.633~4.219) |
| TG[M(P25,P75),mmol/L] | 2.3(1.8,4.0) | 1.9(1.4,2.4) | -1.547b | 0.122 | 1.3(1.1,2.1)a | 1.5(1.0,1.9)a | -0.289b | 0.773 | 0.047(-1.257~1.351) |
| TC( | 5.2±1.7 | 5.1±0.8 | 0.066 | 0.466 | 4.5±1.0a | 4.9±0.6 | -1.591 | 0.074 | 0.408(-0.289~1.105) |
| HDL-C[M(P25,P75),mmol/L] | 1.1(0.8,1.4) | 0.9(0.8,1.1) | -2.052b | 0.040 | 1.1(0.9,1.2) | 1.0(0.9,1.1) | -1.515b | 0.990 | 0.278(0.010~0.545) |
| LDL-C( | 3.5±1.2 | 3.2±0.7 | 1.240 | 0.248 | 2.7±0.9a | 2.8±0.6 | -0.720 | 0.475 | 0.497(-0.109~1.105) |
| UA( | 444.5±115.5 | 443.2±159.1 | 0.072 | 0.973 | 404.2±124.0 | 392.4±101.6 | 0.387 | 0.974 | -16.362(-101.797~69.073) |
| ALT [M(P25,P75),U/L] | 48.5(23.5,118.1) | 48.5(32.2,88.8) | -0.706b | 0.841 | 26.0(17.6,40.8)a | 29.4(20.2,51.7)a | -0.215b | 0.654 | -3.427(-46.702~39.845) |
| AST[M(P25,P75),U/L] | 29.1(20.5,63.2) | 25.4(20.3,48.6) | -0.045b | 0.537 | 21.6(17.7,30.2)a | 21.9(17.8,31.8)a | -0.127b | 0.847 | 10.278(-24.631~45.189) |
| 变量 | 单因素Logistic回归分析 | 多因素Logistic回归分析 | ||
|---|---|---|---|---|
| OR(95%CI) | P值 | OR(95%CI) | P值 | |
| 年龄 | 0.949(0.888~1.014) | 0.118 | ||
| 身高 | 0.988(0.929~1.063) | 0.712 | ||
| 体质量 | 1.022(0.987~1.058) | 0.218 | ||
| BMI | 1.257(1.034~1.528) | 0.022 | 1.257(1.034~1.528) | 0.022 |
| 腰围 | 1.015(0.966~1.066) | 0.561 | ||
| 腰高比 | 0.707(1.582~3.542) | 0.265 | ||
| 体脂肪 | 1.094(1.011~1.184) | 0.026 | ||
| 体脂百分比 | 1.117(1.013~1.231) | 0.026 | ||
| FMI | 1.324(1.055~1.661) | 0.016 | ||
| ASMI | 1.047(0.618~1.775) | 0.865 | ||
| 总肌肉量 | 0.998(0.949~1.050) | 0.948 | ||
| VFA | 1.019(1.003~1.035) | 0.020 | ||
| 心率 | 1.017(0.973~1.063) | 0.464 | ||
| 高血压 | 3.235(0.689~15.187) | 0.137 | ||
| FBG | 0.798(0.386~1.653) | 0.544 | ||
| 2 hFBG | 0.980(0.797~1.205) | 0.849 | ||
| FINS | 1.040(0.953~1.133) | 0.380 | ||
| 2 hFINS | 1.000(0.994~1.007) | 0.883 | ||
| HOMA-IR | 1.027(0.802~1.315) | 0.832 | ||
| TG | 0.946(0.445~2.011) | 0.885 | ||
| TC | 1.696(0.856~3.361) | 0.130 | ||
| HDL-C | 0.587(0.070~4.947) | 0.625 | ||
| LDL-C | 1.533(0.700~3.355) | 0.285 | ||
| UA | 0.999(0.994~1.004) | 0.694 | ||
| ALT | 0.993(0.973~1.014) | 0.521 | ||
| AST | 0.996(0.958~1.036) | 0.852 | ||
| 吸烟史 | 0.524(0.051~5.375) | 0.586 | ||
Table 4 Univariate and multivariate Logistic regression analysis of patients with medium-high ASCVD risk converted into low ASCVD risk
| 变量 | 单因素Logistic回归分析 | 多因素Logistic回归分析 | ||
|---|---|---|---|---|
| OR(95%CI) | P值 | OR(95%CI) | P值 | |
| 年龄 | 0.949(0.888~1.014) | 0.118 | ||
| 身高 | 0.988(0.929~1.063) | 0.712 | ||
| 体质量 | 1.022(0.987~1.058) | 0.218 | ||
| BMI | 1.257(1.034~1.528) | 0.022 | 1.257(1.034~1.528) | 0.022 |
| 腰围 | 1.015(0.966~1.066) | 0.561 | ||
| 腰高比 | 0.707(1.582~3.542) | 0.265 | ||
| 体脂肪 | 1.094(1.011~1.184) | 0.026 | ||
| 体脂百分比 | 1.117(1.013~1.231) | 0.026 | ||
| FMI | 1.324(1.055~1.661) | 0.016 | ||
| ASMI | 1.047(0.618~1.775) | 0.865 | ||
| 总肌肉量 | 0.998(0.949~1.050) | 0.948 | ||
| VFA | 1.019(1.003~1.035) | 0.020 | ||
| 心率 | 1.017(0.973~1.063) | 0.464 | ||
| 高血压 | 3.235(0.689~15.187) | 0.137 | ||
| FBG | 0.798(0.386~1.653) | 0.544 | ||
| 2 hFBG | 0.980(0.797~1.205) | 0.849 | ||
| FINS | 1.040(0.953~1.133) | 0.380 | ||
| 2 hFINS | 1.000(0.994~1.007) | 0.883 | ||
| HOMA-IR | 1.027(0.802~1.315) | 0.832 | ||
| TG | 0.946(0.445~2.011) | 0.885 | ||
| TC | 1.696(0.856~3.361) | 0.130 | ||
| HDL-C | 0.587(0.070~4.947) | 0.625 | ||
| LDL-C | 1.533(0.700~3.355) | 0.285 | ||
| UA | 0.999(0.994~1.004) | 0.694 | ||
| ALT | 0.993(0.973~1.014) | 0.521 | ||
| AST | 0.996(0.958~1.036) | 0.852 | ||
| 吸烟史 | 0.524(0.051~5.375) | 0.586 | ||
| 变量 | 治疗前 | 治疗3个月 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 利拉鲁肽组(n=51) | 二甲双胍组(n=61) | 未用药组(n=60) | 检验统计量值 | P值 | 利拉鲁肽组(n=51) | 二甲双胍组(n=61) | 未用药组(n=60) | 检验统计量值 | P值 | |
| 性别(男/女) | 24/27 | 26/35 | 22/38 | 1.246c | 0.536 | |||||
| ASCVD风险(低危/中高危) | 34/17 | 41/20 | 42/18 | 0.169c | 0.919 | 46/5a | 53/8a | 53/7a | 0.296c | 0.862 |
| 年龄[M(P25,P75),岁] | 31(26,37) | 31(28,39) | 32(29,40) | 1.931 | 0.292 | |||||
| 身高[M(P25,P75),cm] | 170(165,177) | 167(163,174) | 168(163,177) | 0.976 | 0.602 | |||||
| 体质量[M(P25,P75),kg] | 93.3(84.1,102.6) | 91.1(82.6,101.3) | 89.3(81.4,102.7) | 0.988 | 0.505 | 85.6(73.4,96.1)a | 82.7(72.4,92.2)a | 81(73.3,87.7)a | 2.103 | 0.519 |
| TWL[M(P25,P75),%] | 9.4(4.6,12.9) | 9.9(1.1,21.7) | 7.4(7.8,21.8) | 0.041 | 0.960 | |||||
| TWL≥5%[例(%)] | 36.0(70.5) | 37.0(60.7) | 41.0(68.3) | 1.400c | 0.497 | |||||
| TWL≥10%[例(%)] | 24.0(47.1) | 29.0(47.5) | 31.0(51.7) | 0.298c | 0.862 | |||||
| BMI[M(P25,P75),kg/m2] | 32.1(30.5,34.1) | 31.3(29.6,33.8) | 31.1(30.1,34.3) | 2.745 | 0.626 | 28.8(27.5,30.8)a | 28.8(26.4,30.8)* | 28.6(26.9,30.5)a | 1.285 | 0.519 |
| 腰围[M(P25,P75),cm] | 104.5(98.3,112.3) | 102.5(95.5,109.8) | 101.0(95.0,110.0) | 2.223 | 0.179 | 95.5(90.0,103.8)a | 93.0(88.3,97.8)a | 93.0(86.0,100.0)a | 4.073 | 0.161 |
| 腰高比[M(P25,P75)] | 0.6(0.6,0.6) | 0.6(0.6,0.6) | 0.6(0.6,0.6) | 0.570 | 0.251 | 0.6(0.5,0.6)a | 0.6(0.5,0.6)* | 0.5(0.5,0.6)a | 3.772 | 0.359 |
| 体脂肪[M(P25,P75),kg] | 34.2(31.3,40.0) | 34.2(29.8,38.5) | 33.8(29.9,39.6) | 0.052 | 0.524 | 28.4(24.3,33.7)a | 27.9(21.9,33.6)a | 28(21.3,32.3)a | 1.455 | 0.432 |
| 体脂百分比( | 38.3±5.8 | 38.2±5.9 | 38.0±5.9 | 0.033b | 0.974 | 34.8±5.7a | 34.3±7.6a | 33.3±7.4a | 0.728b | 0.485 |
| FMI[M(P25,P75),kg/m2] | 12.3(10.7,13.7) | 11.9(10.4,13.9) | 12.2(10.6,13.4) | 0.191 | 0.887 | 10.3(8.5,11.0)* | 9.7(7.7,12.5)* | 9.8(7.7,11.4)* | 0.588 | 0.711 |
| VFA( | 167.3±39.3 | 165.4±35.9 | 163.2±41.5 | 0.106b | 0.986 | 135.9±36.3a | 131.8±45.1a | 130.1±44.8a | 0.609b | |
| ASMI( | 8.1±0.9 | 8.0±1.7 | 7.9±2.0 | 0.029b | 0.575 | 7.5±0.9a | 7.9±0.9a | 7.9±1.1a | 0.399b | 0.656 |
| 总肌肉量( | 55.0±9.3 | 53.4±9.6 | 53.6±9.8 | 0.237b | 0.850 | 52.4±8.8 | 50.8±8.8 | 51.8±10.5 | 0.422b | 0.545 |
Table 5 Comparison of ASCVD risk and weight loss indicators between liraglutide,metformin,and untreated patients after 3 months of treatment
| 变量 | 治疗前 | 治疗3个月 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 利拉鲁肽组(n=51) | 二甲双胍组(n=61) | 未用药组(n=60) | 检验统计量值 | P值 | 利拉鲁肽组(n=51) | 二甲双胍组(n=61) | 未用药组(n=60) | 检验统计量值 | P值 | |
| 性别(男/女) | 24/27 | 26/35 | 22/38 | 1.246c | 0.536 | |||||
| ASCVD风险(低危/中高危) | 34/17 | 41/20 | 42/18 | 0.169c | 0.919 | 46/5a | 53/8a | 53/7a | 0.296c | 0.862 |
| 年龄[M(P25,P75),岁] | 31(26,37) | 31(28,39) | 32(29,40) | 1.931 | 0.292 | |||||
| 身高[M(P25,P75),cm] | 170(165,177) | 167(163,174) | 168(163,177) | 0.976 | 0.602 | |||||
| 体质量[M(P25,P75),kg] | 93.3(84.1,102.6) | 91.1(82.6,101.3) | 89.3(81.4,102.7) | 0.988 | 0.505 | 85.6(73.4,96.1)a | 82.7(72.4,92.2)a | 81(73.3,87.7)a | 2.103 | 0.519 |
| TWL[M(P25,P75),%] | 9.4(4.6,12.9) | 9.9(1.1,21.7) | 7.4(7.8,21.8) | 0.041 | 0.960 | |||||
| TWL≥5%[例(%)] | 36.0(70.5) | 37.0(60.7) | 41.0(68.3) | 1.400c | 0.497 | |||||
| TWL≥10%[例(%)] | 24.0(47.1) | 29.0(47.5) | 31.0(51.7) | 0.298c | 0.862 | |||||
| BMI[M(P25,P75),kg/m2] | 32.1(30.5,34.1) | 31.3(29.6,33.8) | 31.1(30.1,34.3) | 2.745 | 0.626 | 28.8(27.5,30.8)a | 28.8(26.4,30.8)* | 28.6(26.9,30.5)a | 1.285 | 0.519 |
| 腰围[M(P25,P75),cm] | 104.5(98.3,112.3) | 102.5(95.5,109.8) | 101.0(95.0,110.0) | 2.223 | 0.179 | 95.5(90.0,103.8)a | 93.0(88.3,97.8)a | 93.0(86.0,100.0)a | 4.073 | 0.161 |
| 腰高比[M(P25,P75)] | 0.6(0.6,0.6) | 0.6(0.6,0.6) | 0.6(0.6,0.6) | 0.570 | 0.251 | 0.6(0.5,0.6)a | 0.6(0.5,0.6)* | 0.5(0.5,0.6)a | 3.772 | 0.359 |
| 体脂肪[M(P25,P75),kg] | 34.2(31.3,40.0) | 34.2(29.8,38.5) | 33.8(29.9,39.6) | 0.052 | 0.524 | 28.4(24.3,33.7)a | 27.9(21.9,33.6)a | 28(21.3,32.3)a | 1.455 | 0.432 |
| 体脂百分比( | 38.3±5.8 | 38.2±5.9 | 38.0±5.9 | 0.033b | 0.974 | 34.8±5.7a | 34.3±7.6a | 33.3±7.4a | 0.728b | 0.485 |
| FMI[M(P25,P75),kg/m2] | 12.3(10.7,13.7) | 11.9(10.4,13.9) | 12.2(10.6,13.4) | 0.191 | 0.887 | 10.3(8.5,11.0)* | 9.7(7.7,12.5)* | 9.8(7.7,11.4)* | 0.588 | 0.711 |
| VFA( | 167.3±39.3 | 165.4±35.9 | 163.2±41.5 | 0.106b | 0.986 | 135.9±36.3a | 131.8±45.1a | 130.1±44.8a | 0.609b | |
| ASMI( | 8.1±0.9 | 8.0±1.7 | 7.9±2.0 | 0.029b | 0.575 | 7.5±0.9a | 7.9±0.9a | 7.9±1.1a | 0.399b | 0.656 |
| 总肌肉量( | 55.0±9.3 | 53.4±9.6 | 53.6±9.8 | 0.237b | 0.850 | 52.4±8.8 | 50.8±8.8 | 51.8±10.5 | 0.422b | 0.545 |
| 指标 | 治疗前 | 治疗3个月 | 组间评估平均差异(95%CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 28.0 kg/m2<BMI<32.5 kg/m2组(n=105) | BMI≥32.5 kg/m2组(n=67) | Z(χ2)值 | P值 | 28.0 kg/m2<BMI<32.5 kg/m2组(n=105) | BMI ≥32.5 kg/m2组(n=67) | Z(χ2)值 | P值 | ||
| ASCVD风险(低危/中高危) | 73/32 | 41/26 | 1.270b | 0.260 | 97/8a | 52/15a | 7.702b | 0.006 | |
| TWL[M(P25,P75),%] | 8.4(4.8,12.9) | 9.9(5.8,13.9) | -1.217 | 0.224 | |||||
| TWL≥5%[例(%)] | 78.0(74.3) | 55.0(82.1) | 1.421b | 0.233 | |||||
| TWL≥10%[例(%)] | 44.0(38.1) | 34.0(50.7) | 1.290b | 0.256 | |||||
| 体质量[M(P25,P75),kg] | 84.9(78.7,91.4) | 101.9(91.0,113.2) | -7.842 | <0.001 | 77.6(70.2,85.5)a | 89.3(82.3,98.6)a | -5.726 | <0.001 | -4.555(-9.334~0.223) |
| BMI[M(P25,P75),kg/m2] | 30.4(29.5,31.4) | 34.4(33.4,36.5) | -11.047 | <0.001 | 27.8(26.4,29.0)a | 30.8(29.2,33.1)a | -6.989 | <0.001 | -1.179(-2.327~-0.031) |
| 腰围[M(P25,P75),cm] | 99.1(93.2,105.3) | 106.2(99.4,112.2) | -3.989 | <0.001 | 91.2(85.9,97.2)a | 95.8(89.7,106.3)a | -3.890 | <0.001 | 1.298(-3.123~5.721) |
| 腰高比[M(P25,P75)] | 0.6(0.6,0.6) | 0.6(0.6,0.7) | -3.515 | <0.001 | 0.5(0.5,0.6)a | 0.6(0.5,0.6)a | -2.916 | 0.004 | 0.008(-0.016~0.033) |
| 体脂肪[M(P25,P75),kg] | 31.2(28.1,34.3) | 40.5(35.8,46.9) | -8.308 | <0.001 | 26.4(21.1,29.2)a | 32.3(26.8,38.5)a | -5.351 | <0.001 | -3.232(-6.142~-0.323) |
| 体脂百分比[M(P25,P75),%] | 37.1(33.2,41.2) | 40.8(35.7,45.3) | -3.751 | <0.001 | 33.8(28.0,37.9)a | 35.7(30.3,42.5)a | -2.629 | <0.001 | -1.240(-3.951~1.470) |
| FMI[M(P25,P75),kg/m2] | 11.2(9.4,12.4) | 13.9(12.2,15.8) | -7.164 | <0.001 | 9.3(7.4,10.8)a | 10.9(8.8,13.7)a | -4.570 | <0.001 | -0.951(-1.980~0.078) |
| VFA[M(P25,P75),cm2] | 149.8(125.8,174.1) | 186.8(167.4,29.8) | -6.550 | 0.001 | 120.5(90.5,146.4)a | 151.1(112.3,175.6)a | -4.197 | <0.001 | -9.499(-24.690~5.691) |
| ASMI[M(P25,P75),kg/m2] | 7.8(7.2,8.4) | 8.9(8.0,9.4) | -5.830 | <0.001 | 7.6(6.9,8.3) | 8.3(7.6,9.1)a | -3.892 | 0.012 | -0.232(-0.763~0.298) |
| 总肌肉量[M(P25,P75),kg] | 48.9(44.1,57.8) | 56.8(49.2,65.0) | -4.255 | <0.001 | 47.7(42.9,56.8) | 54.5(46.4,61.3) | -3.012 | 0.010 | -2.321(-6.341~1.698) |
Table 6 Comparing ASCVD risk and weight loss indicators after 3 months of treatment based on BMI stratification
| 指标 | 治疗前 | 治疗3个月 | 组间评估平均差异(95%CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 28.0 kg/m2<BMI<32.5 kg/m2组(n=105) | BMI≥32.5 kg/m2组(n=67) | Z(χ2)值 | P值 | 28.0 kg/m2<BMI<32.5 kg/m2组(n=105) | BMI ≥32.5 kg/m2组(n=67) | Z(χ2)值 | P值 | ||
| ASCVD风险(低危/中高危) | 73/32 | 41/26 | 1.270b | 0.260 | 97/8a | 52/15a | 7.702b | 0.006 | |
| TWL[M(P25,P75),%] | 8.4(4.8,12.9) | 9.9(5.8,13.9) | -1.217 | 0.224 | |||||
| TWL≥5%[例(%)] | 78.0(74.3) | 55.0(82.1) | 1.421b | 0.233 | |||||
| TWL≥10%[例(%)] | 44.0(38.1) | 34.0(50.7) | 1.290b | 0.256 | |||||
| 体质量[M(P25,P75),kg] | 84.9(78.7,91.4) | 101.9(91.0,113.2) | -7.842 | <0.001 | 77.6(70.2,85.5)a | 89.3(82.3,98.6)a | -5.726 | <0.001 | -4.555(-9.334~0.223) |
| BMI[M(P25,P75),kg/m2] | 30.4(29.5,31.4) | 34.4(33.4,36.5) | -11.047 | <0.001 | 27.8(26.4,29.0)a | 30.8(29.2,33.1)a | -6.989 | <0.001 | -1.179(-2.327~-0.031) |
| 腰围[M(P25,P75),cm] | 99.1(93.2,105.3) | 106.2(99.4,112.2) | -3.989 | <0.001 | 91.2(85.9,97.2)a | 95.8(89.7,106.3)a | -3.890 | <0.001 | 1.298(-3.123~5.721) |
| 腰高比[M(P25,P75)] | 0.6(0.6,0.6) | 0.6(0.6,0.7) | -3.515 | <0.001 | 0.5(0.5,0.6)a | 0.6(0.5,0.6)a | -2.916 | 0.004 | 0.008(-0.016~0.033) |
| 体脂肪[M(P25,P75),kg] | 31.2(28.1,34.3) | 40.5(35.8,46.9) | -8.308 | <0.001 | 26.4(21.1,29.2)a | 32.3(26.8,38.5)a | -5.351 | <0.001 | -3.232(-6.142~-0.323) |
| 体脂百分比[M(P25,P75),%] | 37.1(33.2,41.2) | 40.8(35.7,45.3) | -3.751 | <0.001 | 33.8(28.0,37.9)a | 35.7(30.3,42.5)a | -2.629 | <0.001 | -1.240(-3.951~1.470) |
| FMI[M(P25,P75),kg/m2] | 11.2(9.4,12.4) | 13.9(12.2,15.8) | -7.164 | <0.001 | 9.3(7.4,10.8)a | 10.9(8.8,13.7)a | -4.570 | <0.001 | -0.951(-1.980~0.078) |
| VFA[M(P25,P75),cm2] | 149.8(125.8,174.1) | 186.8(167.4,29.8) | -6.550 | 0.001 | 120.5(90.5,146.4)a | 151.1(112.3,175.6)a | -4.197 | <0.001 | -9.499(-24.690~5.691) |
| ASMI[M(P25,P75),kg/m2] | 7.8(7.2,8.4) | 8.9(8.0,9.4) | -5.830 | <0.001 | 7.6(6.9,8.3) | 8.3(7.6,9.1)a | -3.892 | 0.012 | -0.232(-0.763~0.298) |
| 总肌肉量[M(P25,P75),kg] | 48.9(44.1,57.8) | 56.8(49.2,65.0) | -4.255 | <0.001 | 47.7(42.9,56.8) | 54.5(46.4,61.3) | -3.012 | 0.010 | -2.321(-6.341~1.698) |
| 指标 | 治疗前 | 治疗3个月 | 组间评估平均差异(95%CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 男性组(n=73) | 女性组(n=99) | 检验统计量值 | P值 | 男性组(n=73) | 女性组(n=99) | 检验统计量值 | P值 | ||
| ASCVD风险(低危/中高危) | 43/30 | 71/28 | 3.086c | 0.079 | 63/10a | 87/11a | 0.238c | 0.626 | |
| TWL[M(P25,P75),%] | 8.1(2.9,13.0) | 9.8(5.9,13.7) | -1.190 | 0.234 | |||||
| TWL≥5%[例(%)] | 52.0(71.2) | 81.0(81.8) | 2.685c | 0.101 | |||||
| TWL≥10%[例(%)] | 31.0(42.4) | 47.0(47.5) | 0.425c | 0.514 | |||||
| 体质量[M(P25,P75),kg] | 98.4(87.8,109.2) | 83.8(79.5,92.5) | -5.126 | <0.001 | 87.2(82.2,97.3)a | 75.1(68.6,83.1)a | -6.190 | <0.001 | -1.495(-4.956~1.964) |
| BMI[M(P25,P75),kg/m2] | 31.6(30.2,34.1) | 31.5(30.0,33.9) | -0.469 | <0.001 | 29.1(27.2,30.9)a | 28.5(26.4,30.2)a | -0.970 | 0.821 | -0.227(-1.089~0.633) |
| 腰围( | 106.7±10.5 | 99.3±11.0 | 4.377b | <0.001 | 98.2±10.3a | 91.6±7.8a | 4.762b | <0.001 | 0.748(-2.643~4.139) |
| 腰高比[M(P25,P75)] | 0.6(0.6,0.6) | 0.6(0.6,0.6) | -1.070 | 0.284 | 0.6(0.5,0.6)a | 0.6(0.5,0.6)a | -0.685 | 0.494 | 0.001(-0.018~0.021) |
| 体脂肪[M(P25,P75),kg] | 33.2(27.4,39.6) | 34.7(30.7,39.6) | -0.837 | 0.403 | 25.5(21.1,32.2)a | 28.4(23.7,32.0)a | -2.004 | 0.045 | 1.471(-1.117~4.061) |
| 体脂百分比( | 35.2±4.9 | 41.4±6.3 | -7.084b | <0.001 | 29.4±5.8a | 37.4±5.8a | -8.956b | <0.001 | 1.735(-0.551~4.022) |
| FMI[M(P25,P75),kg/m2] | 10.9(9.5,12.8) | 12.7(11.7,14.7) | -4.077 | <0.001 | 8.3(7.2,10.2)a | 10.5(9.0,11.8)a | -4.799 | <0.001 | 0.475(-0.456~1.406) |
| VFA( | 156.3±38.4 | 171.8±41.6 | -2.444b | 0.016 | 117.3±39.7a | 140.3±42.2a | -3.744b | <0.001 | 8.754(-3.931~21.440) |
| ASMI[M(P25,P75),kg/m2] | 8.9(8.3,9.4) | 7.7(7.2,8.2) | -6.585 | <0.001 | 8.7(8.2,9.1) | 7.3(6.8,7.7)a | -9.212 | <0.001 | -0.436(-0.871~-0.001) |
| 总肌肉量[M(P25,P75),kg] | 60.8(53.8,66.4) | 46.7(42.9,50.8) | -7.920 | <0.001 | 58.8(55.3,63.2) | 43.8(40.9,48.1)a | -9.813 | <0.001 | -2.407(-5.388~0.573) |
Table 7 Comparing ASCVD risk and weight loss indicators after 3 months of treatment based on gender stratification
| 指标 | 治疗前 | 治疗3个月 | 组间评估平均差异(95%CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 男性组(n=73) | 女性组(n=99) | 检验统计量值 | P值 | 男性组(n=73) | 女性组(n=99) | 检验统计量值 | P值 | ||
| ASCVD风险(低危/中高危) | 43/30 | 71/28 | 3.086c | 0.079 | 63/10a | 87/11a | 0.238c | 0.626 | |
| TWL[M(P25,P75),%] | 8.1(2.9,13.0) | 9.8(5.9,13.7) | -1.190 | 0.234 | |||||
| TWL≥5%[例(%)] | 52.0(71.2) | 81.0(81.8) | 2.685c | 0.101 | |||||
| TWL≥10%[例(%)] | 31.0(42.4) | 47.0(47.5) | 0.425c | 0.514 | |||||
| 体质量[M(P25,P75),kg] | 98.4(87.8,109.2) | 83.8(79.5,92.5) | -5.126 | <0.001 | 87.2(82.2,97.3)a | 75.1(68.6,83.1)a | -6.190 | <0.001 | -1.495(-4.956~1.964) |
| BMI[M(P25,P75),kg/m2] | 31.6(30.2,34.1) | 31.5(30.0,33.9) | -0.469 | <0.001 | 29.1(27.2,30.9)a | 28.5(26.4,30.2)a | -0.970 | 0.821 | -0.227(-1.089~0.633) |
| 腰围( | 106.7±10.5 | 99.3±11.0 | 4.377b | <0.001 | 98.2±10.3a | 91.6±7.8a | 4.762b | <0.001 | 0.748(-2.643~4.139) |
| 腰高比[M(P25,P75)] | 0.6(0.6,0.6) | 0.6(0.6,0.6) | -1.070 | 0.284 | 0.6(0.5,0.6)a | 0.6(0.5,0.6)a | -0.685 | 0.494 | 0.001(-0.018~0.021) |
| 体脂肪[M(P25,P75),kg] | 33.2(27.4,39.6) | 34.7(30.7,39.6) | -0.837 | 0.403 | 25.5(21.1,32.2)a | 28.4(23.7,32.0)a | -2.004 | 0.045 | 1.471(-1.117~4.061) |
| 体脂百分比( | 35.2±4.9 | 41.4±6.3 | -7.084b | <0.001 | 29.4±5.8a | 37.4±5.8a | -8.956b | <0.001 | 1.735(-0.551~4.022) |
| FMI[M(P25,P75),kg/m2] | 10.9(9.5,12.8) | 12.7(11.7,14.7) | -4.077 | <0.001 | 8.3(7.2,10.2)a | 10.5(9.0,11.8)a | -4.799 | <0.001 | 0.475(-0.456~1.406) |
| VFA( | 156.3±38.4 | 171.8±41.6 | -2.444b | 0.016 | 117.3±39.7a | 140.3±42.2a | -3.744b | <0.001 | 8.754(-3.931~21.440) |
| ASMI[M(P25,P75),kg/m2] | 8.9(8.3,9.4) | 7.7(7.2,8.2) | -6.585 | <0.001 | 8.7(8.2,9.1) | 7.3(6.8,7.7)a | -9.212 | <0.001 | -0.436(-0.871~-0.001) |
| 总肌肉量[M(P25,P75),kg] | 60.8(53.8,66.4) | 46.7(42.9,50.8) | -7.920 | <0.001 | 58.8(55.3,63.2) | 43.8(40.9,48.1)a | -9.813 | <0.001 | -2.407(-5.388~0.573) |
| 指标 | 治疗前 | 治疗3个月 | 组间评估平均差异(95%CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 18~30岁组(n=58) | ≥30岁组(n=114) | 检验统计量值 | P值 | 18~30岁组(n=58) | ≥30岁组(n=114) | 检验统计量值 | P值 | ||
| ASCVD风险(低危/中高危) | 41/17 | 73/41 | 0.515c | 0.473 | 48/10 | 102/12a | 2.223c | 0.136 | |
| TWL[M(P25,P75),%] | 9.5(5.7,14.3) | 8.7(5.5,13.3) | -0.397 | 0.692 | |||||
| TWL≥5%[例(%)] | 46.0(79.3) | 87.0(76.3) | 0.197c | 0.657 | |||||
| TWL≥10%[例(%)] | 26.0(44.8) | 52.0(45.6) | 0.010c | 0.922 | |||||
| 体质量( | 97.3±13.1 | 89.6±13.6 | 3.562b | <0.001 | 87.7±13.2a | 80.8±12.6a | 3.328b | 0.176 | 0.841(-2.781~4.464) |
| BMI[M(P25,P75),kg/m2] | 32.9(30.7,35.1) | 31(29.9,33.4) | -3.487 | <0.001 | 29.0(26.5,31.1)a | 28.6(26.9,30.4)a | -2.558 | 0.535 | 0.344(-0.555~1.244) |
| 腰围[M(P25,P75),cm] | 103.8(97.1,109.8) | 100.4(94.5,106.1) | -2.624 | 0.003 | 94.4(89.1,102.3)a | 93.1(86.4,100.5)a | -2.749 | 0.103 | 1.167(-2.376~4.710) |
| 腰高比[M(P25,P75)] | 0.6(0.6,0.6) | 0.6(0.6,0.6) | -1.560 | 0.119 | 0.6(0.5,0.6)a | 0.6(0.5,0.6)a | -1.581 | 0.114 | 0.006(-0.014~0.027) |
| 体脂肪[M(P25,P75),kg] | 37.7(29.8,43.5) | 33.7(30.5,38.2) | -3.249 | 0.001 | 29.0(22.3,33.7)a | 26.5(21.6,31.8)a | -3.011 | 0.119 | 1.120(-1.592~3.832) |
| 体脂百分比( | 39.4±6.8 | 38.3±6.3 | 1.079b | 0.226 | 35.3±7.5a | 33.4±6.7a | 1.679b | 0.170 | -0.233(-2.640~2.172) |
| FMI[M(P25,P75),kg/m2] | 12.4(10.4,15.5) | 12.1(10.8,13.2) | -1.943 | 0.052 | 10.1(8.2,12.6)a | 9.7(7.8,10.9)a | -1.598 | 0.099 | 0.434(-0.539~1.409) |
| VFA( | 175.8±43.2 | 159.5±38.3 | 2.493b | 0.014 | 142.9±45.3a | 124.9±40.3a | 2.643b | 0.136 | -0.062(-13.397~13.272) |
| ASMI( | 8.2±1.8 | 7.8±1.7 | 1.193b | 0.024 | 7.8±1.8 | 7.8±0.9 | 0.056b | 0.434 | 0.321(-0.134~0.778) |
| 总肌肉量[M(P25,P75),kg] | 54.5(48.9,63.3) | 49.6(44.6,60.9) | -2.320 | 0.020 | 48.7(44.2,61.5) | 50.8(42.3,57.4) | -1.940 | 0.449 | 1.164(-1.970~4.299) |
Table 8 Comparing ASCVD risk and weight loss indicators after 3 months of treatment based on age stratification
| 指标 | 治疗前 | 治疗3个月 | 组间评估平均差异(95%CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 18~30岁组(n=58) | ≥30岁组(n=114) | 检验统计量值 | P值 | 18~30岁组(n=58) | ≥30岁组(n=114) | 检验统计量值 | P值 | ||
| ASCVD风险(低危/中高危) | 41/17 | 73/41 | 0.515c | 0.473 | 48/10 | 102/12a | 2.223c | 0.136 | |
| TWL[M(P25,P75),%] | 9.5(5.7,14.3) | 8.7(5.5,13.3) | -0.397 | 0.692 | |||||
| TWL≥5%[例(%)] | 46.0(79.3) | 87.0(76.3) | 0.197c | 0.657 | |||||
| TWL≥10%[例(%)] | 26.0(44.8) | 52.0(45.6) | 0.010c | 0.922 | |||||
| 体质量( | 97.3±13.1 | 89.6±13.6 | 3.562b | <0.001 | 87.7±13.2a | 80.8±12.6a | 3.328b | 0.176 | 0.841(-2.781~4.464) |
| BMI[M(P25,P75),kg/m2] | 32.9(30.7,35.1) | 31(29.9,33.4) | -3.487 | <0.001 | 29.0(26.5,31.1)a | 28.6(26.9,30.4)a | -2.558 | 0.535 | 0.344(-0.555~1.244) |
| 腰围[M(P25,P75),cm] | 103.8(97.1,109.8) | 100.4(94.5,106.1) | -2.624 | 0.003 | 94.4(89.1,102.3)a | 93.1(86.4,100.5)a | -2.749 | 0.103 | 1.167(-2.376~4.710) |
| 腰高比[M(P25,P75)] | 0.6(0.6,0.6) | 0.6(0.6,0.6) | -1.560 | 0.119 | 0.6(0.5,0.6)a | 0.6(0.5,0.6)a | -1.581 | 0.114 | 0.006(-0.014~0.027) |
| 体脂肪[M(P25,P75),kg] | 37.7(29.8,43.5) | 33.7(30.5,38.2) | -3.249 | 0.001 | 29.0(22.3,33.7)a | 26.5(21.6,31.8)a | -3.011 | 0.119 | 1.120(-1.592~3.832) |
| 体脂百分比( | 39.4±6.8 | 38.3±6.3 | 1.079b | 0.226 | 35.3±7.5a | 33.4±6.7a | 1.679b | 0.170 | -0.233(-2.640~2.172) |
| FMI[M(P25,P75),kg/m2] | 12.4(10.4,15.5) | 12.1(10.8,13.2) | -1.943 | 0.052 | 10.1(8.2,12.6)a | 9.7(7.8,10.9)a | -1.598 | 0.099 | 0.434(-0.539~1.409) |
| VFA( | 175.8±43.2 | 159.5±38.3 | 2.493b | 0.014 | 142.9±45.3a | 124.9±40.3a | 2.643b | 0.136 | -0.062(-13.397~13.272) |
| ASMI( | 8.2±1.8 | 7.8±1.7 | 1.193b | 0.024 | 7.8±1.8 | 7.8±0.9 | 0.056b | 0.434 | 0.321(-0.134~0.778) |
| 总肌肉量[M(P25,P75),kg] | 54.5(48.9,63.3) | 49.6(44.6,60.9) | -2.320 | 0.020 | 48.7(44.2,61.5) | 50.8(42.3,57.4) | -1.940 | 0.449 | 1.164(-1.970~4.299) |
| [1] |
World Obesity Federation. World Obesity Atlas 2024[EB/OL]. [2025-02-20].
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
曲伸,陆灏,宋勇峰. 基于临床的肥胖症多学科诊疗共识(2021年版)[J]. 中华肥胖与代谢病电子杂志,2021,7(4):211-226.
|
| [6] |
|
| [7] |
|
| [8] |
中国血脂管理指南修订联合专家委员会,王增武,李建军,等. 中国血脂管理指南(基层版2024年)[J]. 中国全科医学,2024,27(20):2429-2436. DOI: 10.12114/j.issn.1007-9572.2024.0005.
|
| [9] |
陆菊明. 《中国2型糖尿病防治指南(2020年版)》读后感[J]. 中华糖尿病杂志,2021,13(4):301-304. DOI:10.3760/cma.j.cn115791-20210307-00135.
|
| [10] |
中华医学会,中华医学杂志社,中华医学会全科医学分会,等. 高血压基层诊疗指南(2019年)[J]. 中华全科医师杂志,2019,18(4):301-313. DOI:10.3760/cma.j.issn.1671-7368.2019.04.002.
|
| [11] |
范建高,徐小元,南月敏,等. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志,2024,27(4):494-510.
|
| [12] |
《混合型高脂血症基层诊疗中国专家共识(年)》编写专家组. 混合型高脂血症基层诊疗中国专家共识(2024年)[J]. 中华全科医师杂志,2024,23(9):907-917. DOI:10.3760/cma.j.cn114798-20240523-00476.
|
| [13] |
中华医学会内分泌学分会. 中国高尿酸血症与痛风诊疗指南(2019)[J]. 中华内分泌代谢杂志,2020,36(1):1-13. DOI:10.3760/cma.j.issn.1000-6699.2020.01.001.
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
中华医学会内分泌学分会. 肥胖患者的长期体质量管理及药物临床应用指南(2024版)[J]. 中华内分泌代谢杂志,2024,40(7):545-564. DOI:10.3760/cma.j.cn311282-20240412-00149.
|
| [18] |
|
| [19] |
中华医学会心血管病学分会高血压学组,中华心血管病杂志编辑委员会. 中国高血压患者血压血脂综合管理的专家共识[J]. 中华心血管病杂志,2021,49(6):554-563. DOI:10.3760/cma.j.cn112148-20210202-00128.
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [1] | YI Shanye, YANG Rong, LIAO Xiaoyang, ZHOU Yiheng, LIU Lidi, YANG Ziyu, BAI Jiaxin, JIA Yu, ZHANG Xin. Interpretation of the 2024 Blood Pressure Measurement and Assessment of Arterial Structure and Function: an Expert Group Position Paper [J]. Chinese General Practice, 2026, 29(32): 4690-4694. |
| [2] | LI Lan, LIU Lidi, ZHANG Peng, LI Dongze, YANG Ziyu, CHENG Yonglang, LIAO Xiaoyang, WAN Zhi. Lifestyle Intervention-based Weight Management: an Analysis of Key Highlights from the Partial Update of the 2025 NICE Guideline Overweight and Obesity Management (NG246) [J]. Chinese General Practice, 2026, 29(30): 4353-4359. |
| [3] | SUN Xiuqin, FENG Zhenlong, WEI Lanxuan, ZENG Yuxin, LIU Jinbo, MA Lin, AN Zhantian, WANG Hongyu. Analysis of the Current Status of Metabolic Syndrome among Middle-aged and Elderly People in Shijingshan District, Beijing, and Its Behavioral and Lifestyle Influencing Factors [J]. Chinese General Practice, 2026, 29(30): 4424-4430. |
| [4] | ZHANG Han, CAI Genshen, FENG Zhengwen, ZHANG Kaiyue, LIAN Dongbo, ZHANG Hua, ZHANG Jing. Evaluating the Availability of Health Services for Obesity Comorbidities under Hierarchical Diagnosis and Treatment in Beijing: a Healthcare Institution Survey Study [J]. Chinese General Practice, 2026, 29(28): 4117-4124. |
| [5] | FU Xiaoya, YANG Fei, GU Keyi, GU Handong, WANG Weiqiang. Correlation between Relative Fat Mass Index and Decreased Glomerular Filtration Rate in Patients with Cardiometabolic Comorbidities [J]. Chinese General Practice, 2026, 29(28): 4187-4192. |
| [6] | ZHANG Ying, TANG Yijun, LIU Lidi, JIANG Lihua, JIA Yu, YANG Rong, YANG Ziyu, LIAO Xiaoyang. Management of Cardiovascular Metabolic Risks in Obese Children and Adolescents in China: Based on the 2024 Italian Society of Pediatric Endocrinology and Diabetes Position Paper on Cardiometabolic Risk in Children and Adolescents with Obesity [J]. Chinese General Practice, 2026, 29(27): 3879-3887. |
| [7] | GUO Junchi, ZHANG Mingyan, QIN Guangning, XU Qiang, LU Meijuan. Preliminary Application of the Novel Biomarker TANS01 in Cardiovascular Risk Assessment among Individuals with Phlegm-dampness Constitution [J]. Chinese General Practice, 2026, 29(27): 3924-3930. |
| [8] | ZHAO Yuanyuan, LIU Pulin, DAI Juan, ZHANG Gang, ZHANG Wei, ZHANG Xiaoxia, DENG Qing, YAN Yaqiong. Association Study between Chinese Visceral Adiposity Index and Risk of All-cause and Cause-specific Mortality in the Elderly [J]. Chinese General Practice, 2026, 29(26): 3781-3787. |
| [9] | YANG Rui, LIAO Xiaoyang, HUANG Chuanying, YANG Ziyu, SHEN Can, JIA Yu, LIU Lidi, YANG Rong. Interpretation of the 2024 British and Irish Hypertension Society Position Statement: Investigation and Management of Hypertension in Young People [J]. Chinese General Practice, 2026, 29(26): 3726-3732. |
| [10] | Expert Group on Guidelines for the Assessment, Treatment, and Prevention of Childhood Obesity in China, Professional Committee on Obesity Control in Women and Children, China Maternal and Child Health Research Association. Guidelines for the Assessment, Treatment, and Prevention of Childhood Obesity in China (Second Edition) [J]. Chinese General Practice, 2026, 29(23): 3233-3252. |
| [11] | HAN Congcong, QIU Xinyu, SHAN Chunfang, SONG Ning, CHEN Qingjie, MULADILI· Abudureheman, LI Xiaomei, YANG Yining, ZHAO Qian. Impact of Metabolic Obesity Phenotype on Long-term Prognosis after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome [J]. Chinese General Practice, 2026, 29(21): 2950-2958. |
| [12] | ZHANG Ke, ZENG Xianchang, ZOLZAYA Enkhzaya, ZHU Yelin, HUANG Yiwen, LIU Zhenxiu, TAO Feng. Effect of Xiere Xingpi Yin on Eating Behaviors and Weight-related Outcomes in Patients with Obesity: a Randomized Controlled Trial [J]. Chinese General Practice, 2026, 29(20): 2759-2765. |
| [13] | REYILAI· Maimaiti, ZHOU Yiran, WU Yun, LIU Zhencheng, LU Yaoqin, WU Haiyan. Association between Novel Obesity Indicators and Cardiovascular Disease Risk in Hypertensive Patients [J]. Chinese General Practice, 2026, 29(20): 2836-2845. |
| [14] | CHEN Xiangyang, HUANG Hongmei, LI Sheyu. Prevention and Management of Adult Obesity: Progress and Trends from Six Keywords in 2025 [J]. Chinese General Practice, 2026, 29(20): 2753-2758. |
| [15] | WU Zhen, XI Yaqi, HU Linlin. Characteristics of Policy Instrument Selection and Combination for Weight Management in China: a Content Analysis of National Policy Documents (2016-2025) [J]. Chinese General Practice, 2026, 29(20): 2766-2774. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||